Cell Survival and Death in Oxidant Lung Injury
Cell Survival and Death in Oxidant Lung Injury
批准号:
7388820
负责人:
Michael A O'Reilly
金额:
$38.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-07-01 至 2011-03-31
关键词:
AffectAging-Related ProcessAlveolar CellAnti-Inflammatory AgentsAnti-inflammatoryAntioxidantsApoptosisApoptoticAsthmaCDKN1A geneCell CycleCell Cycle CheckpointCell DeathCell Fate ControlCell LineCell SurvivalCellsCessation of lifeChronicCytoprotectionDactinomycinDecision MakingDiseaseEquilibriumFamilyGene ExpressionGene FamilyGenesGeneticGenetic TranscriptionGenotoxic StressGrowthHalf-LifeHyperoxiaImmunologicsInflammationInjuryLungMalignant NeoplasmsMediatingMediator of activation proteinMouse Cell LineOxidantsOxidative StressOxygenPathway interactionsPatientsPhenotypePost-Transcriptional RegulationProcessProductionProtein p53ProteinsPublic HealthReactive Oxygen SpeciesReperfusion InjuryResearchResearch PersonnelRespiratory distressRoleS-Phase FractionStimulusTP53 geneTestingTherapeuticTimeTissuesbasebcl-xlong proteincell growthcell injuryconceptgenetically modified cellshuman BCL2L1 proteininhibitor/antagonistinjuredinsightkillingsloss of functionlung injurymacromoleculemembermouse modelnovel therapeuticsoncoprotein p21preventpro-apoptotic proteinprogramsprotective effectrepairedtissue oxygenation
中文摘要
描述(申请人提供):当患者遭受呼吸窘迫时,高氧血症经常被用来增强组织的氧合。不幸的是,它的治疗效果受到氧化细胞损伤和肺细胞死亡的限制。修复氧化损伤或启动细胞死亡的决定是由控制细胞命运的基因决定的,例如肿瘤抑制基因P53。P53介导的细胞存活的主要决定因素是细胞周期蛋白依赖的激酶抑制因子p21。与p21是一个重要的促进生存的分子相一致,缺乏p21的小鼠和细胞株很快就会屈服于高氧。在寻找p21保护高氧的机制时,p21被发现可以防止暴露在高氧中的细胞中Bclxl的丢失。细胞功能的获得和丧失的研究提供了实验证据,证明了抗凋亡基因Bcl2家族成员Bclxl是p21介导的高氧保护作用的相关靶点。初步研究表明,p21还调节其他抗细胞凋亡成员的表达。相反,p21不改变促凋亡蛋白Bax或Bak的表达。基于这些观察,我们建议检验p21通过调节抗凋亡成员的表达来预防高氧的假设。利用转基因细胞系和小鼠模型,Aim 1将确定在高氧过程中受p21调控的所有抗凋亡成员,Aim 2将确定高氧和p21如何调节它们的表达,Aim 3将确定它们是否介导了p21的细胞保护作用。这些研究的成功完成将阐明p21如何促进被高氧破坏的细胞的存活,并为氧化肺中细胞命运的决定提供新的见解。研究与公共卫生的相关性。由于持续氧化应激是哮喘、慢性炎症、缺血/再灌注损伤、癌症、衰老过程和许多其他疾病的潜在原因,了解p21如何在高氧条件下控制细胞生长和生存将为促进公共健康提供新的机会。
英文摘要
DESCRIPTION (provided by applicant): Hyperoxia is often used to enhance tissue oxygenation when patients are suffering from respiratory distress. Unfortunately, its therapeutic benefits are limited by oxidative cell injury and death to pulmonary cells. The decision to repair oxidative damage or initiate cell death is dictated by genes, such as the tumor suppressor p53, that control cell fate. The major determinant of p53- mediated cell survival is the cyclin-dependent kinase inhibitor p21. Consistent with p21 being an important pro-survival molecule, mice and cell lines lacking p21 quickly succumb to hyperoxia. While searching for mechanisms by which p21 protects against hyperoxia, p21 was discovered to prevent the loss of Bcl-XL in cells exposed to hyperoxia. Gain and loss of function studies in cell lines provided experimental proof that Bcl-XL, an anti-apoptotic member of the Bcl-2 gene family, is a relevant target of p21-mediated protection against hyperoxia. Preliminary studies indicate p21 also regulates expression of other anti-apoptotic members of the Bcl-2 family. In contrast, p21 does not alter expression of the pro-apoptotic proteins Bax or Bak. Based upon these observations, we propose to test the hypothesis that p21 protects against hyperoxia by regulating expression of anti- apoptotic members of the Bcl-2 family. Using genetically modified cell line and mouse models, Aim 1 will identify all anti-apoptotic members of the Bcl-2 family whose expression is regulated by p21 during hyperoxia, Aim 2 will determine how hyperoxia and p21 regulates their expression, and Aim 3 will determine whether they mediate the cytoprotective effects of p21. Successful completion of these studies will clarify how p21 promotes survival of cells damaged by hyperoxia and provide new insight into how cell fate decisions are made in the oxidized lung. Relevance of Research for Public Health. Because persistent oxidative stress is an underlying cause of asthma, chronic inflammation, ischemia/reperfusion injury, cancer, the aging process, and many other diseases, understanding how p21 controls cell growth and survival during hyperoxia could provide new opportunities for promoting public health.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of early life hyperoxia on mesenchymal stem cell fate: their impact on age related disease
-
批准号:10475250
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2021
-
负责人:Michael A O'Reilly
-
依托单位:
Role of early life hyperoxia on mesenchymal stem cell fate: their impact on age related disease
-
批准号:10312537
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2021
-
负责人:Michael A O'Reilly
-
依托单位:
Effect of Neonatal Hyperoxia on Alveolar Development and Infection
-
批准号:9172674
-
项目类别:
-
资助金额:$11.51万
-
财政年份:2008
-
负责人:Michael A O'Reilly
-
依托单位:
Effect of Neonatal Hyperoxia on Alveolar Development and Infection
-
批准号:9000732
-
项目类别:
-
资助金额:$38.38万
-
财政年份:2008
-
负责人:Michael A O'Reilly
-
依托单位:
Effect of Neonatal Hyperoxia on Alveolar Development and Infection
-
批准号:10001048
-
项目类别:
-
资助金额:$53.66万
-
财政年份:2008
-
负责人:Michael A O'Reilly
-
依托单位:
Effect of Neonatal Hyperoxia on Alveolar Development and Infection
-
批准号:9767838
-
项目类别:
-
资助金额:$53.66万
-
财政年份:2008
-
负责人:Michael A O'Reilly
-
依托单位:
Effect of Neonatal Hyperoxia on Alveolar Development and Infection
-
批准号:8630581
-
项目类别:
-
资助金额:$38.38万
-
财政年份:2008
-
负责人:Michael A O'Reilly
-
依托单位:
Effect of Neonatal Hyperoxia on Alveolar Development and Infection
-
批准号:7591323
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2008
-
负责人:Michael A O'Reilly
-
依托单位:
Effect of Neonatal Hyperoxia on Alveolar Development and Infection
-
批准号:10246362
-
项目类别:
-
资助金额:$53.66万
-
财政年份:2008
-
负责人:Michael A O'Reilly
-
依托单位:
Effect of Neonatal Hyperoxia on Alveolar Development and Infection
-
批准号:8197382
-
项目类别:
-
资助金额:$38.12万
-
财政年份:2008
-
负责人:Michael A O'Reilly
-
依托单位:
Effect of Neonatal Hyperoxia on Alveolar Development and Infection
-
批准号:7746428
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2008
-
负责人:Michael A O'Reilly
-
依托单位:
Effect of Neonatal Hyperoxia on Alveolar Development and Infection
-
批准号:7989991
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2008
-
负责人:Michael A O'Reilly
-
依托单位:
Core--Instrumentation Facility
-
批准号:6867266
-
项目类别:
-
资助金额:$17.65万
-
财政年份:2005
-
负责人:Michael A O'Reilly
-
依托单位:
DNA Repair and Replication in Oxidant Lung Injury
-
批准号:6924577
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2002
-
负责人:Michael A O'Reilly
-
依托单位:
DNA Repair and Replication in Oxidant Lung Injury
-
批准号:6756459
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2002
-
负责人:Michael A O'Reilly
-
依托单位:
Cell survival and death in oxidant lung injury
-
批准号:8661214
-
项目类别:
-
资助金额:$37.85万
-
财政年份:2002
-
负责人:Michael A O'Reilly
-
依托单位:
DNA Repair and Replication in Oxidant Lung Injury
-
批准号:6508966
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2002
-
负责人:Michael A O'Reilly
-
依托单位:
Cell survival and death in oxidant lung injury
-
批准号:8279197
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2002
-
负责人:Michael A O'Reilly
-
依托单位:
Cell Survival and Death in Oxidant Lung Injury
-
批准号:7266475
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2002
-
负责人:Michael A O'Reilly
-
依托单位:
DNA Repair and Replication in Oxidant Lung Injury
-
批准号:6629485
-
项目类别:
-
资助金额:$35.44万
-
财政年份:2002
-
负责人:Michael A O'Reilly
-
依托单位: